Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
In other news, the FDA moves to restrict use of fluoride supplements by children and the EPA approves more pesticides that some consider PFAS ...
Aurinia Pharmaceuticals Inc. (AUPH) has recently garnered a “Buy” rating from Jefferies analyst Maury Raycroft, a change that could have significant implications for investors. With a target price of ...
Fintel on MSN
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH)
Fintel reports that on November 7, 2025, Jefferies upgraded their outlook for Aurinia Pharmaceuticals (NasdaqGM:AUPH) from ...
Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance ...
23hOpinion
The FDA’s Meltdown Escalates
An ethics complaint leads to a resignation, and the agency shifts approval standards.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback